Table 2.
Patient characteristics at the time of kidney biopsy
| Characteristics | First Biopsy, n=67 | Second Biopsy, n=44 | Third Biopsy, n=9 | Fourth Biopsy, n=5 |
|---|---|---|---|---|
| Active ANCA GN | 63 (94) | 35 (80) | 7 (78) | 5 (100) |
| Extrarenal involvement | 52 (78) | 22 (50) | 3 (34) | 3 (60) |
| Maintenance treatmenta | 16 (36) | 4 (44) | 1 (20) | |
| Serum creatinine, mg/dl | 1.95 (1.23–3.62) | 2.22 (1.43–3.81) | 3.40 (2.14–4.03) | 1.64 (1.26–3.37) |
| AKI, n/N | 18/43 | 5/9 | 3/5 | |
| Proteinuria, g/d | 0.92 (0.26–2.16) | 0.73 (0.39–2.05) | 1.72 (0.93–3.90) | 0.71 (0.30–1.55) |
| Hematuria, n/N | 61/66 | 40/43 | 8/9 | 5/5 |
| C-reactive protein, mg/L | 50 (6–116) | 14 (2–60) | 16 (4–50) | 61 (21–138) |
| Urinary soluble CD163, ng/mmol | 524 (92–1957) | 381 (15–794) | 527 (178–1040) | 169 (37–861) |
| Serum soluble CD25, ng/L | 1303 (785–1986) | 987 (736–1599) | 1114 (740–2091) | 556 (352–2871) |
| Urinary soluble CD25, ng/mmol | 242 (134–422) | 131 (71–236) | 137 (24–311) | 217 (115–617) |
Data are presented as medians (interquartile ranges) or numbers (%), unless stated otherwise. ANCA GN, ANCA-associated GN.
a
Any form of immunosuppressive therapy ≤6 months prior to biopsy.